Is There Evidence for IGF1R-Stimulating Abs in Graves’ Orbitopathy Pathogenesis?
In this review, we summarize the evidence against direct stimulation of insulin-like growth factor 1 receptors (IGF1Rs) by autoantibodies in Graves’ orbitopathy (GO) pathogenesis. We describe a model of thyroid-stimulating hormone (TSH) receptor (TSHR)/IGF1R crosstalk and present evidence that obser...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/18/6561 |
| _version_ | 1797554287767715840 |
|---|---|
| author | Christine C. Krieger Susanne Neumann Marvin C. Gershengorn |
| author_facet | Christine C. Krieger Susanne Neumann Marvin C. Gershengorn |
| author_sort | Christine C. Krieger |
| collection | DOAJ |
| description | In this review, we summarize the evidence against direct stimulation of insulin-like growth factor 1 receptors (IGF1Rs) by autoantibodies in Graves’ orbitopathy (GO) pathogenesis. We describe a model of thyroid-stimulating hormone (TSH) receptor (TSHR)/IGF1R crosstalk and present evidence that observations indicating IGF1R’s role in GO could be explained by this mechanism. We evaluate the evidence for and against IGF1R as a direct target of stimulating IGF1R antibodies (IGF1RAbs) and conclude that GO pathogenesis does not involve directly stimulating IGF1RAbs. We further conclude that the preponderance of evidence supports TSHR as the direct and only target of stimulating autoantibodies in GO and maintain that the TSHR should remain a major target for further development of a medical therapy for GO in concert with drugs that target TSHR/IGF1R crosstalk. |
| first_indexed | 2024-03-10T16:29:50Z |
| format | Article |
| id | doaj.art-9491ae088505434897e9636050723a1f |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T16:29:50Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-9491ae088505434897e9636050723a1f2023-11-20T12:56:36ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-09-012118656110.3390/ijms21186561Is There Evidence for IGF1R-Stimulating Abs in Graves’ Orbitopathy Pathogenesis?Christine C. Krieger0Susanne Neumann1Marvin C. Gershengorn2Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, Bethesda, MD 20892, USALaboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, Bethesda, MD 20892, USALaboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, Bethesda, MD 20892, USAIn this review, we summarize the evidence against direct stimulation of insulin-like growth factor 1 receptors (IGF1Rs) by autoantibodies in Graves’ orbitopathy (GO) pathogenesis. We describe a model of thyroid-stimulating hormone (TSH) receptor (TSHR)/IGF1R crosstalk and present evidence that observations indicating IGF1R’s role in GO could be explained by this mechanism. We evaluate the evidence for and against IGF1R as a direct target of stimulating IGF1R antibodies (IGF1RAbs) and conclude that GO pathogenesis does not involve directly stimulating IGF1RAbs. We further conclude that the preponderance of evidence supports TSHR as the direct and only target of stimulating autoantibodies in GO and maintain that the TSHR should remain a major target for further development of a medical therapy for GO in concert with drugs that target TSHR/IGF1R crosstalk.https://www.mdpi.com/1422-0067/21/18/6561IGF1RTSHRreceptor crosstalkGraves’ orbitopathyIGF1R antibodiesTSHR antibodies |
| spellingShingle | Christine C. Krieger Susanne Neumann Marvin C. Gershengorn Is There Evidence for IGF1R-Stimulating Abs in Graves’ Orbitopathy Pathogenesis? International Journal of Molecular Sciences IGF1R TSHR receptor crosstalk Graves’ orbitopathy IGF1R antibodies TSHR antibodies |
| title | Is There Evidence for IGF1R-Stimulating Abs in Graves’ Orbitopathy Pathogenesis? |
| title_full | Is There Evidence for IGF1R-Stimulating Abs in Graves’ Orbitopathy Pathogenesis? |
| title_fullStr | Is There Evidence for IGF1R-Stimulating Abs in Graves’ Orbitopathy Pathogenesis? |
| title_full_unstemmed | Is There Evidence for IGF1R-Stimulating Abs in Graves’ Orbitopathy Pathogenesis? |
| title_short | Is There Evidence for IGF1R-Stimulating Abs in Graves’ Orbitopathy Pathogenesis? |
| title_sort | is there evidence for igf1r stimulating abs in graves orbitopathy pathogenesis |
| topic | IGF1R TSHR receptor crosstalk Graves’ orbitopathy IGF1R antibodies TSHR antibodies |
| url | https://www.mdpi.com/1422-0067/21/18/6561 |
| work_keys_str_mv | AT christineckrieger isthereevidenceforigf1rstimulatingabsingravesorbitopathypathogenesis AT susanneneumann isthereevidenceforigf1rstimulatingabsingravesorbitopathypathogenesis AT marvincgershengorn isthereevidenceforigf1rstimulatingabsingravesorbitopathypathogenesis |